Survivin: A target from brain cancer to neurodegenerative disease

Critical Reviews in Biochemistry and Molecular Biology

Volumn 45, Issue 6, 2010, Pages 535-554

  Baratchi, Sara ^a   Kanwar, Rupinder K ^a   Kanwar, Jagat R ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

apoptosis; apoptosis inhibitor protein; neurodegenerative disease; neuroprotection; survivin

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLASPARTYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; DNA VACCINE; EM 1421; FLAVOPIRIDOL; FLT3 LIGAND; GROWTH FACTOR; PROTEIN CDK1; PYRIMIDINE DERIVATIVE; RIBOZYME; SDX 308; SHEPERDIN; STAT3 PROTEIN; SURVIVIN; SURVIVIN C84A; SURVIVIN D53A; SURVIVIN T34A; TANESPIMYCIN; TERAMEPROCOL; UNCLASSIFIED DRUG;

APOPTOSIS; BRAIN CANCER; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG TARGETING; HUMAN; MITOCHONDRION; MITOSIS; NEOPLASM; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CASPASES; CELL CYCLE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MICROTUBULES; MITOSIS; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS;

EID: 78549269769     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2010.516740     Document Type: Review

References (238)

1. Agell N, Bachs O, Rocamora N and Villalonga P. 2002. Modulation of the Ras/Raf/MEK/ERK pathway by Ca2+, and calmodulin. Cell Signal 14:649-654.
2. Altieri DC. 2003. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46-54.
3. Altieri DC. 2006. The case for survivin as a regulator of microtu-bule dynamics and cell-death decisions. Curr Opin Cell Biol 18:609-615.
4. Altieri DC. 2008. Opinion - Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61-70.
5. Altura RA, Olshefski RS, Jiang Y and Boue DR. 2003. Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade. Brit J Cancer 89:1743-1749.
6. Alubaidi MR, Hollyfeld JG, Overbeek PA and Baehr W. 1992. Photoreceptor degeneration induced by the expression of simian virus-40 large tumor-antigen in the retina of transgenic mice. Proc Natl Acad Sci USA 89:1194-1198.
7. Ambrosini G, Adida C and Altieri DC. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921.
8. Amiri S, Movahedin M, Mowla SJ, Hajebrahimi Z and Tavallaei M. 2009. Diferential gene expression and alternative splicing of survivin following mouse sciatic nerve injury. Spinal Cord 47:739-744.
9. Aoki K, Zubkov AY, Ross IB and Zhang JH. 2002. Terapeutic efect of caspase inhibitors in the prevention of apoptosis and reversal of chronic cerebral vasospasm. J Clin Neurosci 9:672-677.
10. Arendt T, Holzer M and Gartner U. 1998. Neuronal expression of cycline dependent kinase inhibitors of the INK4 family in Alzheimer's disease. J Neural Transm 105:949-960.
11. Ashkenazi A. 2002. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420-430.
12. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T and Inuzuka M. 2004. Identifcation of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Comm 314:902-907.
13. Bao RD, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA and Hamilton TC. 2002. Activation of cancer-specifc gene expression by the survivin promoter. J Natl Cancer Inst 94: 522-528.
14. Baratchi S, Kanwar RK, Khoshmanesh K, Vasu P, Ashok C, Hittu M, Parratt A, Krishnakumar S, Sun XY, Sahoo SK and Kanwar JR. 2009. Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases. Curr Nanosci 5:15-25.
15. Baratchi S, Kanwar RK, Cheung CHA and Kanwar JR. 2010. Proliferative and protective efects of SurR9-C84A on diferentiated neural cells. J Neuroimmunol 227:120-32.
16. Berman SB, Chen YB, Qi B, McCafery JM, Rucker EB, Goebbels S, Nave KA, Arnold BA, Jonas EA, Pineda FJ and Hardwick JM. 2009. Bcl-x(L) increases mitochondrial fssion, fusion, and biomass in neurons. J Cell Biol 184:707-719.
17. Boman B, Kopellovich L, Siracusa LD, Zhang T, Henderson K, Cofer Z, Buchberg AM, Fields JZ and Otevrel T. 2009. A Tcf4-GFP reporter mouse model for monitoring efects of apc mutations during intestinal tumorigenesis. Mol Carcinogen 48:821-831.
18. Bradley EW, Ruan MM and Oursler MJ. 2008. PAK1 is a novel MEK-independent raf target controlling expression of the IAP sur-vivin in M-CSF-mediated osteoclast survival. J Cell Physiol 217:752-758.
19. Bradley WD and Koleske AJ. 2009. Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts. J Cell Sci 122:3441-3454.
20. Braun JS, Novak R, Herzog KH, Bodner SM, Cleveland JL and Tuomanen EI. 1999. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med 5:298-302.
21. Brenner C and Kroemer G. 2000. Apoptosis - mitochondria - the death signal integrators. Science 289:1150-1151.
22. Bulat N and Widmann C. 2009. Caspase substrates and neurodegen-erative diseases. Brain Res Bull 80:251-267.
23. Burns KA, Ayoub AE, Breunig JJ, Adhami F, WengWL, Colbert MC, Rakic P and Kuan CY. 2007. Nestin-CreER mice reveal DNA synthesis by nonapoptotic neurons following cerebral ischemia-hypoxia. Cereb Cortex 17:2585-2592.
24. Burstein E and Duckett CS. 2003. Dying for NF-kappa B? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr Opin Cell Biol 15:732-737.
25. Busser J, Geldmacher DS and Herrup K. 1998. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 18:2801-2807.
26. Caldas H, Honsey LE and Altura RA. 2005a. Survivin 2 alpha: a novel survivin splice variant expressed in human malignancies. Mol Cancer 4:11.
27. Caldas H, Jiang YY, Holloway MP, Fangusaro J, Mahotka C, Conway EM and Altura RA. 2005b. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24:1994-2007.
28. Cao LH, Yan XM, Wu YH, Hu HR, Li Q, Zhou T, Jiang SM and Yu L. 2006. Survivin mutant (Surv-DD70, 71AA) disrupts the interaction of Survivin with Aurora B and causes multinucleation in HeLa cells. Biochem Biophys Res Comm 346:400-407.
29. Carmena M. 2008. Cytokinesis: the fnal stop for the chromosomal passengers. Biochem Soc Trans 36:367-370.
30. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song QH and Loefer J. 2004. Survivin enhances radiation resistance in primary human gliob-lastoma cells via caspase-independent mechanisms. Oncogene 23:7494-7506.
31. Charriaut-Marlangue C. 2004. Apoptosis: A target for neuroprotection. Terapie 59:185-190.
32. Chen CL, Cen L, Kohout J, Hutzen B, Chan C, Hsieh FC, Loy A, Huang V, Cheng G and Lin J. 2008. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer 7:78.
33. Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, Bennett F, Krajewski S, Krajewska M, Welsh K, Reed JC and Ng SC. 2000. Down-regulation of survivin by antisense oligonucle-otides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2:235-241.
34. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ and Hung MC. 2004. Cancer-specifc activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ter 11:740-747.
35. Cheung CHA, Kanwar J and Krissansen GW. 2006. A cell-permeable dominant-negative Survivin protein as a tool to understand how Survivin maintains tumour cell survival. EJC Suppl 4:488.
36. Cheung CHA, Chen HH, Cheng LT, Lyu KW, Kanwar JR and Chang JY. 2010. Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Mol Cancer. 9:77.
37. Christie LA, Su JH, Tu CH, Dick MC, Zhou J and Cotman CW. 2007. Diferential regulation of inhibitors of apoptosis proteins in Alzheimer's disease brains. Neurobiol Dis 26:165-173.
38. Christoferson DE and Yuan J. 2010. Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 22:263-268.
39. Ciesielski MJ, Apfel L, Barone TA, Castro CA, Weiss TC and Fenstermaker RA. 2006. Antitumor efects of a xenogeneic sur-vivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 55:1491-1503.
40. Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A and Fenstermaker RA. 2010. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother 59:1211-1221.
41. Citron BA, Arnold PM, Haynes NG, Ameenuddin S, Farooque M, Santacruz K and Festof BW. 2008. Neuroprotective efects of caspase-3 inhibition on functional recovery and tissue sparing after acute spinal cord injury. Spine 33:2269-2277.
42. Colak A, Karaoglan A, Barut S, Kokturk S, Akyildiz AI and Tasyurekli M. 2005. Neuroprotection and functional recovery after application of the caspase-9 inhibitor z-LEHD-fmk in a rat model of traumatic spinal cord injury. J Neurosurg - Spine 2: 327-334.
43. Colnaghi R, Connell CM, Barrett RMA and Wheatley SP. 2006. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 281:33450-33456.
44. Delvaeye M, De Vriese A, Zwerts F, Betz I, Moons M, Autiero M and Conway EM. 2009. Role of the 2 zebrafsh survivin genes in vascu-lo-angiogenesis, neurogenesis, cardiogenesis and hematopoiesis. BMC Dev Biol 9:25.
45. Demir O, Singh S, Klimaschewski L and Kurnaz IA. 2009. From birth till death: neurogenesis, cell cycle, and neurodegeneration. Anat Rec 292:1953-1961.
46. Dence CS, Sun X, Mach RH and Welch MJ. 2005. [C-11]-methylated LY2181308, An antisense oligonucleotide to survivin: radiochem-ical synthesis and preliminary rodent biodistribution studies. J Labelled Compd Rad 48:S161-S161.
47. Dickson MA, Shah, M.A, Rathkopf D, Tse A, Carvajal RD, Wu N, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, and Schwartz GK. 2010. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor favopiridol. Cancer Chemother Pharmacol published online DOI 10.1007/ s00280-010-1269-1.
48. Dietz GPH, Dietz B and Bahr M. 2007. Bcl-X-L protects cerebellar granule neurons against the late phase, but not against the early phase of glutamate-induced cell death. Brain Res 1164:136-141.
49. Dohi T, Xia F and Altieri DC. 2007. Compartmentalized phosphor-ylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 27:17-28.
50. Donnini S, Solito R, Monti M, Balduini W, Carloni S, Cimino M, Bampton ETW, Pinon LGP, Nicotera P, Torpe PE and Ziche M. 2009. Prevention of ischemic brain injury by treatment with the membrane penetrating apoptosis inhibitor, TAT-BH4. Cell Cycle 8:1271-1278.
51. Dziennis S and Alkayed NJ. 2008. Role of signal transducer and activator of transcription 3 in neuronal survival and regeneration. Rev Neurosci 19:341-361.
52. Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, Mann W, Kovacs AF and Stauber RH. 2007. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol 211:532-540.
53. Esteve PO, Chin HG and Pradhan S. 2005. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proc Natl Acad Sci USA 102:1000-1005.
54. Eyers P. 2009. Survivin(g) phosphorylation? Survivin phosphorylation, mitosis and apoptosis. Cell Cycle 8:183-184.
55. Farkas LM and Huttner WB. 2008. The cell biology of neural stem and progenitor cells and its signifcance for their proliferation versus diferentiation during mammalian brain development. Curr Opin Cell Biol 20:707-715.
56. Feddersen RM, Ehlenfeldt R, Yunis WS, Clark HB and Orr HT. 1992. Disrupted cerebellar cortical development and progressive degeneration of Purkinje-cells in SV40-T antigen transgenic mice. Neuron 9:955-966.
57. Fei Q, Zhang HY, Fu LL, Dai XL, Gao BM, Ni M, Ge C, Li JJ, Ding X, Ke YW, Yao XB and Zhu JD. 2008. Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes. Acta Bioch Bioph Sin 40:466-477.
58. Feng YZ, Fratkin JD and Leblanc MH. 2003. Inhibiting caspase-9 after injury reduces hypoxic ischemic neuronal injury in the cortex in the newborn rat. Neurosci Lett 344:201-204.
59. Ferreiro E, Eufrasio A, Pereira C, Oliveira CR and Rego AC. 2007. Bcl-2 overexpression protects against amyloid-beta and prion toxicity in GT1-7 neural cells. J Alzheimers Dis 12:223-228.
60. Fest S, Huebener N, Gaedicke G and Lode HN. 2008. A novel survivin minigene DNA vaccine induces an efective anti-neuroblastoma immune response. Eur J Pediat 167:362-362.
61. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, Sessa WC and Altieri DC. 2003. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 100:13791-13796.
62. Friedlander RM. 2003. Mechanisms of disease: Apoptosis and caspases in neurodegenerative diseases. New Engl J Med 348:1365-1375.
63. Friedlander RM, Brown RH, Gagliardini V, Wang J and Yuan JY. 1997. Inhibition of ICE slows ALS in mice. Nature 388:31-31.
64. Gal A, Szilagyi G, Wappler E, Safrany G and Nagy Z. 2008. Bcl-2 or Bcl-XL gene therapy reduces apoptosis and increases plasticity protein GAP-43 in PC12 cells. Brain Res Bull 76:349-353.
65. Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S, Carlson E, Sagi SA, Chevallier N, Jin K, Greenberg DA and Bredesen DE. 2006. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci USA 103:7130-7135.
66. Garrity-Moses ME, Teng QS, Krudy C, Yang J, Federici T and Boulis NM. 2006. X-linked inhibitor of apoptosis protein gene-based neuroprotection for the peripheral nervous system. Neurosurgery 59:172-181.
67. Gassmann R, Carvalho A, Henzing AJ, Ruchaud S, Hudson DE, Honda R, Nigg EA, Gerlof DL and Earnshaw WC. 2004. Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J Cell Biol 166:179-191.
68. Ghosh JC, Dohi T, Raskett CM, Kowalik TF and Altieri DC. 2006. Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res 66:11576-11579.
69. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, Van Klaveren RJ, Chaudhary S, Gunther, A and Shamsili, S. 2009. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 27:4481-4486.
70. Gidday JM. 2006. Cerebral preconditioning and ischaemic tolerance. Nature Rev Neurosci 7:437-448.
71. Gleave ME and Monia BP. 2005. Antisense therapy for cancer. Nat Rev Cancer 5:468-479.
72. Gotz R, Karch C, Digby MR, Troppmair J, Rapp UR and Sendtner M. 2000. The neuronal apoptosis inhibitory protein suppresses neu-ronal diferentiation and apoptosis in PC12 cells. Hum Mol Genet 9:2479-2489.
73. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA and Jove R. 2006. Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12:11-19.
74. Gualco E, Urbanska K, Perez-Liz G, Sweet T, Peruzzi F, Reiss K and Del Valle L. 2009. IGF-IR dependent expression of Survivin is required for T-Antigen mediated protection from Apoptosis and proliferation of neural progenitors. J Neurovirol 15:P68.
75. Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ, Andreef M, Meli M, Colombo G and Altieri DC. 2006. Antileukemic activity of shepherdin and molecular diversity of Hsp90 inhibitors. J Natl Cancer Inst 98:1068-1077.
76. Hagberg H, Mallard C, Rousset CI and Wang XY. 2009. Apoptotic Mechanisms in the Immature Brain: Involvement of Mitochondria. J Child Neurol 24:1141-1146.
77. Hahn HP, Pang M, He J, Hernandez JD, Yang RY, Li LY, Wang X, Liu FT and Baum LG. 2004. Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death Difer 11:1277-1286.
78. Hansen MR, Roehm PC, Xu NY and Green SH. 2007. Overexpression of Bcl-2 or Bcl-xL prevents spiral ganglion neuron death and inhibits neurite growth. Dev Neurobiol 67:316-325.
79. Havran LM, Chong DC, Childers WE, Dollings PJ, Dietrich A, Harrison BL, Marathias V, Tawa G, Aulabaugh A, Cowling R, Kapoor B, Xu WX, Mosyak L, Moy F, Hum W T, Wood A and Robichaud AJ. 2009. 3,4-Dihydropyrimido(1,2-a)indol-10(2H)- ones as potent non-peptidic inhibitors of caspase-3. Bioorg Med Chem 17:7755-7768.
80. Hayashi Y, Jikihara I, Yagi T, Fukumura M, Ohashi Y, Ohta Y, Takagi H and Maeda M. 2001. Immunohistochemical investigation of caspase-1 and efect of caspase-1 inhibitor in delayed neu-ronal death after transient cerebral ischemia. Brain Res 893: 113-120.
81. Hengartner MO. 2000. The biochemistry of apoptosis. Nature 407:770-776.
82. Herrup K and Yang Y. 2007. Cell cycle regulation in the postmi-totic neuron: oxymoron or new biology? Nature Rev Neurosci 8:368-378.
83. Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R and Bertolotto C. 2008. IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 128:1499-1505.
84. Hoeglinger GU, Breunig JJ, Depboylu C, Rouaux C, Michel PP, Alvarez-Fischer D, Boutillier A-L, Degregori J, Oertel WH, Rakic P, Hirsch EC and Hunot S. 2007. The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci USA 104:3585-3590.
85. Honda R, Korner R and Nigg EA. 2003. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 14:3325-3341.
86. Hong Z, Qin L, Zhen L, Mei YW and Guo YL. 2008. The protection of Bcl-2 overexpression on rat cortical neuronal injury caused by analogous ischemia/reperfusion in vitro. Neurosci Res 62:140-146.
87. Honma I, Kitamura H, Torigoe T, Takahashi A, Tanaka T, Sato E, Hirohashi Y, Masumori N, Tsukamoto T and Sato N. 2009. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother 58:1803-1809.
88. Honore S, Pasquier E and Braguer D. 2005. Understanding microtu-bule dynamics for improved cancer therapy. Cell Mol Life Sci 62:3039-3056.
89. Inoue S, Davis DP, Drummond JC, Cole DJ and Patel PM. 2006. The combination of isofurane and caspase 8 inhibition results in sustained neuroprotection in rats subject to focal cerebral ischemia. Anesth Analg 102:1548-1555.
90. Islam A, Kageyama H, Hashizume K, Kaneko Y and Nakagawara A. 2000. Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identifcation of a novel dominant-negative isoform, survivin-beta/2B. Med Ped Oncol 35:550-553.
91. Janssens V, Goris J and Van Hoof C. 2005. PP2A: the expected tumor suppressor. Curr Opin Genet Dev 15:34-41.
92. Jiang LB, Liu XQ, Li B, He XJ, Jin YL, Li LQ, Gao F and Wang NL. 2008. Heat shock proteins and survivin: Relationship and efects on proliferation index of retinoblastoma cells. Histol Histopathol 23:827-831.
93. Jiang YY, De Bruin A, Caldas H, Fangusaro J, Hayes J, Conway EM, Robinson ML and Altura RA. 2005. Essential role for survivin in early brain development. J Neurosci 25:6962-6970.
94. Jordan J, Cena V and Prehn JHM. 2003. Mitochondrial control of neuron death and its role in neurodegenerative disorders. J Physiol Biochem 59:129-141.
95. Jordan-Sciutto KL, Wang GJ, Murphey-Corb M and Wiley CA. 2002. Cell cycle proteins exhibit altered expression patterns in lentivi-ral-associated encephalitis. J Neurosci 22:2185-2195.
96. Kaneko N, Kita A, Nakahara T, Nakata M, Koutoku H and Sasamata M. 2010. Tumor regression induced by YM155, a novel, survivin suppressant, in human difuse large B-cell lymphoma models. J Pharmacol Sci 112:260P-260P.
97. Kang BH and Altieri DC. 2006. Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J Biol Chem 281:24721-24727.
98. Kanwar JR. 2005. Anti-infammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease. Curr Med Chem 12:2947-2962.
99. Kanwar JR, Shen WP, Kanwar RK, Berg RW and Krissansen GW. 2001. Efects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 93:1541-1552.
100. Kanwar JR, Kanwar RK and Krissansen GW. 2004a. Simultaneous neu-roprotection and blockade of infammation reverses autoimmune encephalomyelitis. Brain 127:1313-1331.
101. Kanwar JR, Shen WP, Kanwar RK, Sun XY, Berg RW and Krissansen GW. 2004b. Survivin antagonists and antisense HIF-1 alpha stimulate the generation of tumor-specifc CTLs: May be benefcial for the treatment of large lymphomas. Cancer Gene Ter 11:853.
102. Kanwar JR, Kanwar RK, Burrow H and Baratchi S. 2009a. Recent Advances on the Roles of NO in Cancer and Chronic Infammatory Disorders. Curr Med Chem 16:2373-2394.
103. Kanwar JR, Mahidhara G and Kanwar RK. 2009b. Recent Advances in Nanoneurology for Drug Delivery to the Brain. Curr Nanosci 5:441-448.
104. Kanwar RK, Cheung CHA, Chang JY and Kanwar JR. 2010. Recent Advances in Anti-Survivin Treatments for Cancer. Curr Med Chem 17:1509-1515.
105. Karaoglan A, Kaya E, Akdemir O, Sagmanligil A, Bilguvar K, Cirakoglu B, Sahan E, Erdogan N, Barut S and Colak A. 2008. Neuroprotective efects of Ac.YVAD.cmk on experimental spinal cord injury in rats. Surg Neurol 69:561-567.
106. Khanna N, Tomas G, Stern J and Frazer N. 2006. Efects of EM-1421, a novel transcription inhibitor, on cervical intraepithelial neopla-sia: Results of a pilot phase I/II study. EJC Suppl 4:489.
107. Kim CH, Woo SJ, Park JS, Kim HS, Park MY, Park SD, Hong YK and Kim TG. 2007. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 122:615-622.
108. Kim S, Kang JH, Qiao JB, Tomas RP, Evers BM and Chung DH. 2004. Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J Ped Surg 39:516-521.
109. Kita A, Nakahara T, Yamanaka K, Nakata M, Kaneko N, Koutoku H and Sasamata M. 2009. YM155: A small molecule survivin suppressant with potent antitumor efect in human breast cancer models. Cancer Res 69:692S-693S.
110. Knauer SK, Bier C, Habtemichael N and Stauber RH. 2006. The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep 7:1259-1265.
111. Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rodel F, Klein-Hitpass L, Kovacs AF, Doring C, Hansmann ML, Hofmann WK, Kunkel M, Brochhausen C, Engels K, Lippert BM, Mann W and Stauber RH. 2007. The survivin isoform Survivin-3B is cytopro-tective and can function as a chromosomal passenger complex protein. Cell Cycle 6:1502-1509.
112. Knoblach SM, Alroy DA, Nikolaeva M, Cernak I, Stoica BA and Faden AI. 2004. Caspase inhibitor z-DEVD-fmk attenuates cal-pain and necrotic cell death in vitro and after traumatic brain injury. J Cereb Blood Flow Metab 24:1119-1132.
113. Krepela E, Dankova P, Moravcikova E, Krepelova A, Prochazka J, Cermak J, Schutzner J, Zatloukal P and Benkova K. 2009. Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol 35:1449-1462.
114. Kroemer G. 2001. Mitochondrial control of apoptosis. B Acad Nat Med Paris 185:1135-1143.
115. Kunigal S, Lakka SS, Sodadasu PK, Estes N and Rao JS. 2009. Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. Int J Oncol 34:1209-1220.
116. Lang SA, Schachtschneider P, Moser C, Mori A, Hackl C, Gaumann A, Batt D, Schlitt HJ, Geissler EK and Stoeltzing O. 2008. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct efects on tumor cells, endothelial cells, and pericytes. Mol Cancer Terapeut 7:3509-3518.
117. Lanza IR and Nair KS. 2010. Mitochondrial function as a determinant of life span. Pfug Arch Eur J Phy 459:277-289.
118. LeBlanc HN and Ashkenazi A. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death Difer 10:66-75.
119. Lee SI, Kim BG, Hwang DH, Kim HM and Kim SU. 2009. Overexpression of Bcl-X-L in human neural stem cells promotes graft survival and functional recovery following transplantation in spinal cord injury. J Neurosci Res 87:3186-3197.
120. Lens SMA, Rodriguez JA, Vader G, Span SW, Giaccone G and Medema RH. 2006. Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell 17:1897-1909.
121. Lentzsch S, Elliitt G and Roodman GD. 2007. SDX-308 and SDX-101, non-steroidal anti-infammatory drugs, as therapeutic candidates for treating Hematologic malignancies including myeloma. Arch Pharm 340:511-516.
122. Li F. 2005. Role of survivin and its splice variants in tumorigenesis. Brit J Cancer 92:212-216.
123. Li FZ and Ling XA. 2006. Survivin study: An update of "What is the next wave?". J Cell Physiol 208:476-486.
124. Li FZ, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC. 1998. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580-584.
125. Li FZ, Ackermann EJ, Bennett C F, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC and Altieri DC. 1999. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nature Cell Biol 1:461-466.
126. Li FZ, Yang J, Ramnath N, Javle MM and Tan DF. 2005. Nuclear or cytoplasmic expression of survivin: What is the signifcance? Int J Cancer 114:509-512.
127. Li H, Chen Y, Jones AF, Sanger RH, Collis L P, Flannery R, McNay EC, Yu TX, Schwarzenbacher R, Bossy B, Bossy-Wetzel E, Bennett MVL, Pypaert M, Hickman JA, Smith PJS, Hardwick JM and Jonas EA. 2008. Bcl-X-L induces Drp1-dependent synapse formation in cultured hippocampal neurons. Proc Natl Acad Sci USA 105:2169-2174.
128. Li LY, Luo L and Wang XD. 2001. Endonuclease G is an apop-totic DNase when released from mitochondria. Nature 412: 95-99.
129. Li M, Ona VO, Chen M, Kaul M, Tenneti L, Zhang X, Stieg PE, Lipton SA and Friedlander RM. 2000. Functional role and therapeutic implications of neuronal caspase-1 and-3 in a mouse model of traumatic spinal cord injury. Neuroscience 99:333-342.
130. Li TF, Lu CZ, Xia ZL, Xiao BG and Luo YM. 2006. Inhibition of cas-pase-8 attenuates neuronal death induced by limbic seizures in a cytochrome c-dependent and Smac/DIABLO-independent way. Brain Res 1098:204-211.
131. Li XN, Shu Q, Su JM, Adesina AM, Wong KK, Perlaky L, Antalfy BA, Blaney SM and Lau CC. 2007. Diferential expression of sur-vivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol 33:67-76.
132. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu WH, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR and Byrd JC. 2009. Phase II study of favopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27:6012-6018.
133. Lippert BM, Knauer SK, Fetz V, Mann W and Stauber RH. 2007. Dynamic survivin in head and neck cancer: Molecular mechanism and therapeutic potential. Int J Cancer 121:1169-1174.
134. Liste I, Garcia-Garcia E, Bueno C and Martinez-Serrano A. 2007. Bcl-X-L modulates the diferentiation of immortalized human neural stem cells. Cell Death Difer 14:1880-1892.
135. Liu YWJ, Mee EW, Bergin P, Teoh HH, Connor B, Dragunow M and Faull RLM. 2007. Adult neurogenesis in mesial temporal lobe epilepsy: A review of recent animal and human studies. Curr Pharmaceut Biotechnol 8:187-194.
136. Loefer M, Daugas E, Susin SA, Zamzami N, Metivier D, Nieminen AL, Brothers G, Penninger JM and Kroemer G. 2001. Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor. Faseb J 15:758-767. (Pubitemid 32245994)
137. Lopez RA, Goodman AB, Rhodes M, Blomberg JAL and Heller J. 2007. The anticancer activity of the transcription inhibitor ter-ameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration. Anti-Cancer Drugs 18: 933-939.
138. Lordan S, Mackrill JJ and O'Brien NM. 2009. Oxysterols and mechanisms of apoptotic signaling: implications in the pathology of degenerative diseases. J Nutrit Biochem 20:321-336.
139. Mahotka C, Liebmann J, Wenzel M, Suschek C V, Schmitt M, Gabbert HE and Gerharz CD. 2002. Diferential subcellular localization of functionally divergent survivin splice variants. Cell Death Difer 9:1334-1342.
140. Makrantoni V and Stark MJR. 2009. Efcient chromosome biorien-tation and the tension checkpoint in Saccharomyces cerevisiae both require Bir1. Mol Cell Biol 29:4552-4562.
141. Mantoan L, Stefanova N, Egger KE, Jellinger KA, Poewe W and Wenning GK. 2005. Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple system atrophy). Acta Neuropath 109:191-197.
142. Marambaud P, Dreses-Werringloer U and Vingtdeux V. 2009. Calcium signaling in neurodegeneration. Mol Neurodegen 4:20.
143. Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, Grajeda JPR and Melendez-Zajgla J. 2008. Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res 27:8.
144. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I and Reed JC. 2003. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 22:2729-2740.
145. McLaughlin CT, Kane AG and Auber AE. 2003. MR imaging of heat stroke: external capsule and thalamic T1 shortening and cerebel-lar injury. Am J Neuroradiol 24:1372-1375.
146. McShea A, Harris PLR, Webster KR, Wahl AF and Smith MA. 1997. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 150:1933-1939.
147. Minematsu T, Iwai M, Sugimoto K, Shirai N, Nakahara T, Usui T and Kamimura H. 2009. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9- dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro -1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab Dispos 37:619-628.
148. Minematsu T, Iwai M, Umehara K-I, Usui T and Kamimura H. 2010. Characterization of human organic cation transporter 1 (OCT1/ SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3- (pyrazin-2-ylmethyl)-4,9-dihydro -1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos 38:1-4.
149. Miyata T, Kawaguchi D, Kawaguchi A and Gotoh Y. 2010. Mechanisms that regulate the number of neurons during mouse neocortical development. Curr Opin Neurobiol 20:22-28.
150. Monteghirfo S, Tosetti F, Ambrosini C, Stigliani S, Pozzi S, Frassoni F, Fassina G, Soverini S, Albini A and Ferrari N. 2008. Antileukemia efects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappa B and p53 modulation. Mol Cancer Terapeut 7:2692-2702.
151. Muchmore SW, Chen J, Jakob C, Zakula D, Matayoshi ED, Wu W, Zhang HC, Li FZ, Ng SC and Altieri DC. 2000. Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein sur-vivin. Mol Cell 6:173-182.
152. Nabilsi NH, Broaddus RR and Loose DS. 2009. DNA methylation inhibits p53-mediated survivin repression. Oncogene 28:2046-2050.
153. Nagy Z, Esiri MM, Cato AM and Smith AD. 1997. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropath 94:6-15.
154. Nandi S, Ulasov IV, Tyler MA, Sugihara AQ, Molinero L, Han Y, Zhu ZB and Lesniak MS. 2008. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res 68:5778-5784.
155. Nieto-Rementeria N, Perez-Yarza G, Boyano MD, Apraiz A, Izu R, Diaz-Perez JL and Asumendi A. 2009. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Brit J Dermatol 160:519-526.
156. Nijboer CH, Heijnen CJ, Groenendaal F, May MJ, Van Bel F and Kavelaars A. 2008. A dual role of the NF-kappa B pathway in neonatal hypoxic-ischemic brain damage. Stroke 39:2578-2586.
157. Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ferrigno PK and Wheatley SP. 2006. Molecular analysis of survivin isoforms - evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 281:1286-1295.
158. O'Connor DS, Grossman D, Plescia J, Li FZ, Zhang H, Villa A, Tognin S, Marchisio PC and Altieri DC. 2000. Regulation of apop-tosis at cell division by p34(cdc2) phosphorylation of survivin. Proc Natl Acad Sci USA 97:13103-13107.
159. Okada Y, Sakai H, Kohiki E, Suga E, Yanagisawa Y, Tanaka K, Hadano S, Osuga H and Ikeda JE. 2005. A dopamine D4 receptor antagonist attenuates ischemia-induced neuronal cell damage via upregula-tion of neuronal apoptosis inhibitory protein. J Cereb Blood Flow Metab 25:794-806.
160. Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, Clement G, Yagui-Beltran A, Ray MR, Koizumi K, He BA and Jablons DM. 2008. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Torac Oncol 3:1089-1095.
161. Ona VO, Li MW, Vonsattel JPG, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, Yuan JY, Penney JB, Young AB, Cha JHJ and Friedlander RM. 1999. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399:263-267.
162. Parrish J, Li LL, Klotz K, Ledwich D, Wang XD and Xue D. 2001. Mitochondrial endonuclease G is important for apoptosis in C-elegans. Nature 412:90-94.
163. Pekarsky Y, Garrison PN, Palamarchuk A, Zanesi N, Aqeilan RI, Huebner K, Barnes LD and Croce CM. 2004. Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci USA 101:3775-3779.
164. Pennati M, Folini M and Zafaroni N. 2007. Targeting survivin in cancer therapy: fulflled promises and open questions. Carcinogenesis 28:1133-1139.
165. Perrelet D, Ferri A, Mackenzie AE, Smith GM, Korneluk RG, Liston P, Sagot Y, Terrado J, Monnier D and Kato AC. 2000. IAP family proteins delay motoneuron cell death in vivo. Eur J Neurosci 12:2059-2067.
166. Perrelet D, Ferri A, Liston P, Muzzin P, Korneluk RG and Kato AC. 2002. IAPs are essential for GDNF-mediated neuroprotective efects in injured motor neurons in vivo. Nature Cell Biol 4:175-179.
167. Proskuryakov SY, Konoplyannikov AG and Gabai VL. 2003. Necrosis: a specifc form of programmed cell death? Exp Cell Res 283: 1-16.
168. Pumiglia KM and Decker SJ. 1997. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 94:448-452.
169. Rami A, Bechmann I and Stehle JH. 2008. Exploiting endogenous anti-apoptotic proteins for novel therapeutic strategies in cerebral ischemia. Prog Neurobiol 85:273-296.
170. Ray SK, Karmakar S, Nowak MW and Banik NL. 2006. Inhibition of calpain and caspase-3 prevented apoptosis and preserved elec-trophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate. Neuroscience 139:577-595.
171. Renwick J, Narang MA, Coupland SG, Xuan JY, Baker AN, Brousseau J, Petrin D, Munger R, Leonard BC, Hauswirth WW, Korneluk RG and Tsilfdis C. 2006. XIAP-mediated neuroprotec-tion in retinal ischemia. Gene Ter 13:339-347.
172. Rodel F, Muller B, Sieber R, Leumann W, Sauer R and Rodel C. 2006. Increase of the apoptosis rate and radiation-sensitisation of colorectal cancer cells through an antisense-oligonucleotide (Lilly LY2181308)-mediated inhibition of survivin. Strahlenther Onkol 182:90-90.
173. Roovers K and Assoian RK. 2000. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 22:818-826.
174. Rosa J, Canovas P, Islam A, Altieri DC and Doxsey SJ. 2006. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell 17:1483-1493.
175. Ruchaud S, Carmena M and Earnshaw WC. 2007. The chromosomal passenger complex: One for all and all for one. Cell 131:230-231.
176. Russell JC, Whiting H, Szufita N and Hossain MA. 2008. Nuclear trans-location of X-linked inhibitor of apoptosis (XIAP) determines cell fate after hypoxia ischemia in neonatal brain. J Neurochem 106:1357-1370.
177. Ryan BM, O'Donovan N and Dufy MJ. 2009. Survivin: A new target for anti-cancer therapy. Cancer Treat Rev 35:553-562.
178. Saitoh T, Igura M, Obita T, Ose T, Kojima R, Maenaka K, Endo T and Kohda D. 2007. Tom20 recognizes mitochondrial presequences through dynamic equilibrium among multiple bound states. EMBO J 26:4777-4787.
179. Salomoni P and Calegari F. 2010. Cell cycle control of mammalian neural stem cells: putting a speed limit on G1. Trends Cell Biol 20:233-243.
180. Salvesen GS and Duckett CS. 2002. IAP proteins: Blocking the road to death's door. Nature Rev Mol Cell Biol 3:401-410.
181. Sampath JLMP. 2007. Alternative splice variants of survivin as potential targets in cancer. Current Drug Discov Technol 4:19.
182. Samuel T, Okada K, Hyer M, Welsh K, Zapata JM and Reed JC. 2005. clAP1 localizes to the nuclear compartment and modulates the cell cycle. Cancer Res 65:210-218.
183. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, Saito T, Masuda N, Watanabe H, Taguchi T, Kakihara T, Aoyama Y, Hashimoto Y and Nakagawa K. 2009. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 15:3872-3880.
184. Semba S, Trapasso F, Fabbri M, McCorkell KA, Volinia S, Druck T, Iliopoulos D, Pekarsky Y, Ishii H, Garrison PN, Barnes LD, Croce CM and Huebner K. 2006. Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene 25:2860-2872.
185. Shen CX, Liu WJ, Buck AK and Reske SN. 2009. Pro-apoptosis and anti-proliferation efects of a recombinant dominant-negative surviv-in-T34A in human cancer cells. Anticancer Res 29:1423-1428.
186. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Tompson CB and Tsujimoto Y. 2004. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nature Cell Biol 6:1221-1228.
187. Shioi G, Konno D, Shitamukai A and Matsuzaki F. 2009. Structural basis for self-renewal of neural progenitors in cortical neurogenesis. Cereb Cortex 19:I55-I61.
188. Shishodia S and Aggarwal BB. 2002. Nuclear factor-kappa B activation: A question of life or death. J Biochem Mol Biol 35:28-40.
189. Si Z-H, Zhang X-Q, Tang J-Y. 2009. Efects of electric stimulation treatment on motor function and expression of microtubule-associ-ated protein-2 and survivin of brain tissue in cerebral infarction rats J Clin Neurol 22:4.
190. Skoufas DA, Mollinari C, Lacroix FB and Margolis RL. 2000. Human survivin is a kinetochore-associated passenger protein. J Cell Biol 151:1575-1581.
191. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR and Martin SJ. 1999. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 144:281-292.
192. Smale G, Nichols NR, Brady DR, Finch CE and Horton WE. 1995. Evidence for apoptotic cell-death in Alzheimers-disease. Exp Neurol 133:225-230.
193. Smith MZ, Nagy Z and Esiri MM. 1999. Cell cycle-related protein expression in vascular dementia and Alzheimer's disease. Neurosci Lett 271:45-48.
194. Song ZY and Wu M. 2005. Identifcation of a novel nucleolar localization signal and a degradation signal in Survivin-deltaEx3: a potential link between nucleolus and protein degradation. Oncogene 24:2723-2734.
195. Song ZY, Liu SX, He H, Hoti N, Wang Y, Feng SS and Wu M. 2004. A single amino acid change (Asp 53 -> Ala53) converts survivin from anti-apoptotic to pro-apoptotic. Mol Biol Cell 15:1287-1296.
196. Srinivasula SM, Datta P, Fan XJ, Fernandes-Alnemri T, Huang ZW and Alnemri ES. 2000. Molecular determinants of the caspase-pro-moting activity of Smac/DIABLO and its role in the death receptor pathway. J Biol Chem 275:36152-36157.
197. Stauber RH, Mann W and Knauer SK. 2007. Nuclear and cytoplasmic survivin: Molecular mechanism, prognostic, and therapeutic potential. Cancer Res 67:5999-6002. (Pubitemid 47037475)
198. Sun CH, Nettesheim D, Liu ZH and Olejniczak ET. 2005. Solution structure of human survivin and its binding interface with Smac/ Diablo. Biochemistry 44:11-17.
199. Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loefer M, Costantini P, Ferri KF, Irinopoulou T, Prevost MC, Brothers G, Mak TW, Penninger J, Earnshaw WC and Kroemer G. 2000. Two distinct pathways leading to nuclear apoptosis. J Exp Med 192:571-579.
200. Suzuki H, Sozen T, Hasegawa Y, Chen WQ and Zhang JH. 2009. Caspase-1 inhibitor prevents neurogenic pulmonary edema after subarachnoid hemorrhage in mice. Stroke 40:3872-3875.
201. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreef M and Reed JC. 2000. Expression and prognostic signifcance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6:1796-1803.
202. Tanaka Y, Igarashi S, Nakamura M, Gafni J, Torcassi C, Schilling G, Crippen D, Wood JD, Sawa A, Jenkins NA, Copeland NG, Borchelt DR, Ross CA and Ellerby LM. 2006. Progressive pheno-type and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin. Neurobiol Dis 21:381-391.
203. Teles AVF, Ureshino RP, Dorta DJ, Lopes GS, Hsu YT and Smaili SS. 2008. Bcl-X-L inhibits Bax-induced alterations in mito-chondrial respiration and calcium release. Neurosci Lett 442: 96-99.
204. Timmer T, De Vries EGE and De Jong S. 2002. Fas receptor-mediated apoptosis: a clinical application? J Pathol 196:125-134.
205. Tolosa L, Mir M, Asensio VJ, Olmos G and Llado J. 2008. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinosi-tol 3-kinase. J Neurochem 105:1080-1090.
206. Trapp T, Korhonen L, Besselmann M, Martinez R, Mercer EA and Lindholm D. 2003. Transgenic mice overexpressing XIAP in neurons show better outcome after transient cerebral ischemia. Mol Cell Neurosci 23:302-313.
207. Troost D, Aten J, Morsink F and Dejong J. 1995. Apoptosis in amyo-trophic lateral sclerosis is not restricted to motor neurons. Bcl-2 expression is increased in unafected post-central gyrus. Neuropathol Appl Neurobiol 21:498-504.
208. Tsuji N, Asanuma K, Kobayashi D, Yagihashi A and Watanabe N. 2005. Introduction of a survivin gene-specifc small inhibitory RNA inhibits growth of pancreatic cancer cells. Anticancer Res 25:3967-3972.
209. Tsuruma T, Iwayama Y, Ohmura T, Katsuramaki T, Hata F, Furuhata T, Yamaguchi K, Kimura Y, Torigoe T, Toyota N, Yagihashi A, Hirohashi Y, Asanuma H, Shimozawa K, Okazaki M, Mizushima Y, Nomura N, Sato N and Hirata K. 2008. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Translat Med 6:24.
210. Usmani SZ, Bona R and Li ZH. 2009. 17 AAG for HSP90 Inhibition in cancer - from bench to bedside. Curr Mol Med 9:654-664.
211. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR and Altieri DC. 2007. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 26:2678-2684.
212. Vanoosthuyse V and Hardwick KG. 2009. Overcoming inhibition in the spindle checkpoint. Genes Dev 23:2799-2805.
213. Villapol S, Acarin L, Faiz M, Castellano B and Gonzalez B. 2008. Survivin and heat shock protein 25/27 colocalize with cleaved caspase-3 in surviving reactive astrocytes following excitotoxicity to the immature brain. Neuroscience 153:108-119.
214. Vong QP, Cao K, Li HY, Iglesias PA and Zheng YX. 2005. Chromosome alignment and segregation regulated by ubiquitination of sur-vivin. Science 310:1499-1504.
215. Vucic D and Fairbrother WJ. 2007. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13:5995-6000.
216. Wang CX and Youle RJ. 2009. The role of mitochondria in apoptosis. Ann Rev Genet 43:95-118.
217. Wang J and Lenardo MJ. 2000. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene defciencies. J Cell Sci 113:753-757.
218. Wang R, Lin F, Wang X, Gao P, Dong K, Wei SH, Cheng SY and Zhang HZ. 2007. The therapeutic potential of survivin promoter-driven siRNA on suppressing tumor growth and enhancing radio-sensitivity of human cervical carcinoma cells via downregulating hTERT gene expression. Cancer Biol Ter 6:1295-1301.
219. Wang XY, Zhu CL, Wang XH, Hagberg H, Korhonen L, Sandberg M, Lindholm D and Blomgren K. 2004. X-linked inhibitor of apop-tosis (XIAP) protein protects against caspase activation and tissue loss after neonatal hypoxia-ischemia. Neurobiol Dis 16:179-189.
220. Weis K. 2003. Regulating access to the genome: Nucleocytoplasmic transport throughout the cell cycle. Cell 112:441-451.
221. West AB, Dawson VL and Dawson TM. 2005. To die or grow: Parkinson's disease and cancer. Trends Neurosci 28:348-352.
222. Wheatley SP, Henzing AJ, Dodson H, Khaled W and Earnshaw WC. 2004. Aurora-B phosphorylation in vitro identifes a residue of survivin that is essential for its localization and binding to inner centromere protein (INCENP) in vivo. J Biol Chem 279:5655-5660.
223. Wojda U, Salinska E and Kuznicki J. 2008. Calcium ions in neuronal degeneration. Iubmb Life 60:575-590.
224. Wootz H, Hansson I, Korhonen L and Lindholm D. 2006. XIAP decreases caspase-12 cleavage and calpain activity in spinal cord of ALS transgenic mice. Exp Cell Res 312:1890-1898.
225. Wu B, Ma Q, Khatibi N, Chen W, Sozen T, Cheng O and Tang J 2010. Ac-YVAD-CMK decreases blood-brain barrier degradation by inhibiting caspase-1 activation of interleukin-1β in intracerebral hemorrhage mouse model. Translat Stroke Res 1:57-64.
226. Wu X, Tian F, Okagaki P and Marini AM. 2005. Inhibition of N-methyl-D-aspartate receptors increases paraoxon-induced apoptosis in cultured neurons. Toxicol Appl Pharmacol 208:57-67.
227. Xia F, Canovas PM, Guadagno TM and Altieri DC. 2008. A survivin-Ran complex regulates spindle formation in tumor cells. Mol Cell Biol 28:5299-5311.
228. Xu DG, Crocker SJ, Doucet JP, Stjean M, Tamai K, Hakim AM and Ikeda JE. 1997. Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nat Med 3:997-1004.
229. Yan H, Tomas J, Liu T, Raj D, London N, Tandeski T, Leachman SA, Lee RM and Grossman D. 2006. Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist. Oncogene 25:6968-6974.
230. Yang Y and Herrup K. 2005. Loss of neuronal cell cycle control in ataxia-telangiectasia: A unifed disease mechanism. J Neurosci 25:2522-2529.
231. Yang Y, Geldmacher DS and Herrup K. 2001. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 21:2661-2668.
232. Yang Z, Wang L, Wang HM, Shang XY, Niu W, Li JT and Wu YZ. 2008. A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efciency. Mol Immunol 45:1674-1681.
233. Yin W, Cao GD, Johnnides MJ, Signore AP, Luo YM, Hickey RW and Chen J. 2006. TAT-mediated delivery of Bcl-xL protein is neuro-protective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF. Neurobiol Dis 21:358-371.
234. Zhang QG, Wang RM, Khan M, Mahesh V and Brann DW. 2008. Role of dickkopf-1, an antagonist of the Wnt/beta-catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of tau phosphorylation. J Neurosci 28:8430-8441.
235. Zhang R, Wang T, Li KN, Qin WW, Chen R, Wang K, Jia LT, Zhao J, Wen WH, Meng YL, Yao LB and Yang AG. 2008. A survivin double point mutant has potent inhibitory efect on the growth of hepatocellular cancer cells. Cancer Biol Ter 7:547-554.
236. Zhang R, Xue YY, Lu SD, Wang Y, Zhang LM, Huang YL, Signore AP, Chen J and Sun FY. 2006. Bcl-2 enhances neurogenesis and inhibits apoptosis of newborn neurons in adult rat brain following a transient middle cerebral artery occlusion. Neurobiol Dis 24:345-356.
237. Zhang YH, Park TS and Gidday JN. 2007. Hypoxic preconditioning protects human brain endothelium from ischemic apoptosis by Akt-dependent survivin activation. Am J Physiol - Heart Circul Physiol, 292:H2573-H2581.
238. Zhu DE, Hoti N, Song Z, Jin L, Wu Z, Wu Q and Wu M. 2006. Suppression of tumor growth using a recombinant adeno-viral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model. Cancer Gene Ter 13: 762-770.